Abstract:OBJECTIVE To evaluate the effect and clinical significance of adrenomedulin (ADM) and urotensin-II (UII) on pulmonary hypertension (PH), by detecting their levels of patients with congenital heart disease and pulmonary hypertension. METHODS 52 patients with congenital heart disease who had left-to-right shunt were selected randomly. 52 patients were divided three groups according to pulmonary artery systolic pressure (PASP): group A was not pulmonary hypertension (PASP < 30 mm Hg, n = 17); group B was mild pulmonary hypertension (PASP30-49 mm Hg, n = 18); group C was moderate and severe pulmonary hypertension (PASP > or = 50 mm Hg, n = 17). The plasma levels of ADM and UII were detected at each period by radioimmunoassay (RIA) method. It was analyzed the changes of their levels within pre-operation, 20 mins and 7 days post-operation and the interrelation between them and PASP. RESULTS (1) Following the severity degree of pulmonary hypertension, the plasma levels of ADM increase. There is positive correlation between PAP and plasma level of ADM (pre-operation r = 0.8012, P < 0.01; 20 min post-operation r = 0.6325, P < 0.01; 7 d post-operation r = 0.7126, P < 0.01). (2) Following the severity degree of pulmonary hypertension, the plasma levels of UII don't change obviously. There is no correlation between PAP and plasma level of UII (P > 0.05). (3) The plasma levels of ADM: group A (pre-operation: 33 pg/ml +/- 5 pg/ml, 20 mins post-operation: 29 pg/ml +/- 4 pg/ml, 7 d post-operation: 20 pg/ml +/- 3 pg/ml); group B (pre-operation: 44 pg/ml +/- 8 pg/ml, 20 mins post-operation: 40 pg/ml +/- 6 pg/ml, 7 d post-operation: 34 pg/ml +/- 4 pg/ml); group C (pre-operation: 60 pg/ml +/- 10 pg/ml, 20 mins post-operation: 58 pg/ml +/- 8 pg/ml, 7d post-operation: 38 pg/ml +/- 4 pg/ml). Plasma level of ADM of each group after CPB is lower than that of each group before operation. It is statistical difference only 7 days post-operation (group A q = 5.41, P < 0.01; group B q = 4.76, P < 0.01; group C q = 6.32, P < 0.01). (4) The plasma levels of UII: group A (pre-operation: 2.2 pmol/L +/- 0.5 pmol/L, 20 mins post-operation: 2.2 pmol/L +/- 0.44 pmol/L, 7 d post-operation: 2.2 pmol/L +/- 0.6 pmol/L); group B (pre-operation: 2.7 pmol/L +/- 0.6 pmol/L, 20 mins post-operation: 2.6 pmol/L +/- 0.6 pmol/L, 7 d post-operation: 2.6 pmol/L +/- 0.5 pmol/L); group C (pre-operation: 2.9 pmol/L +/- 0.6 pmol/L, 20 mins post-operation: 2.6 pmol/L +/- 0.7 pmol/L, 7 d post-operation: 2.8 pmol/L +/- 0.4 pmol/L). Compared with that of each group before operation, Plasma level of UII of each group after operation is no obvious difference (P > 0.05). CONCLUSION (1) Following the severity degree of pulmonary hypertension, the plasma levels of ADM increase. ADM plays an important role in the formation of pulmonary hypertension and restructure. (2) Following the severity degree of pulmonary hypertension, the plasma levels of UII don't change obviously. There is no correlation between PAP and plasma level of UII, but UII may be play an important role in the formation of pulmonary hypertension and restructure. (3) Measuring the levels of ADM may be a reliable method to follow the change of pulmonary pressure and worsening of pulmonary hypertension.

Serum Apelin-Angiotensin Ii Expression And Aktphosphorylation Pathway In Children With Congenital Heart Disease Complicated With Pulmonary Hypertension

The effection of idiopathic pulmonary hypertension on endothelial progenitor cells and bone morphogenetic protein-2

Levels of plasma endothelin and calcitonin gene-related peptide in children with congenital heart disease and pulmonary hypertension

Study of Angiotensinii Level Fluctuation in Patients with Congenital Heart Diseases Pre- and Post-Interventional Therapy

Relationship Between Level of Serum Vascular Endothelial Growth Factor, Transforming Growth Factor Β1 and Pulmonary Artery Pressure in Children with Congenital Heart Disease Before and after Severe Pulmonary Hypertension Surgery

Proteomic Study Reveals Altered Carbamyl-Phosphate Synthetase I In Congenital Heart Disease-Associated Pulmonary Arterial Hypertension

Clinical study of targeting therapy and transcatheter closure for congenital heart disease with severe ;pulmonary hypertension

The relationship between endothelial progenitor cells and pulmonary arterial hypertension in children with congenital heart disease

Study of plasma levels of adipokines Apelin12 and Apelin13 in the patient with chronic heart failure classified by NYHA grading

The Alteration and Clinical Significance of Plasma Endothelin-1 in Patients with Congenital Heart Disease Accompanied by Secondary Pulmonary Hypertension

Serum high mobility group box 1 levels and its clinical significance in patients with pulmonary arterial hypertension associated with congenital heart disease.

Evaluating the role of serum uric acid in the risk stratification and therapeutic response of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD)

Effects of pulmonary artery pressure on neurosecretory hormone in patients with congenital heart disease

Plasma Proteomic Study in Pulmonary Arterial Hypertension Associated with Congenital Heart Diseases

Changes in Complement Factor H-related Protein 2 in Children with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease and Its Potential Clinical Significance

[Study on the Effect of Adrenomedulin and Urotensin-Ii on Pulmonary Hypertension of Patients with Congenital Heart Disease].

Non-congenital Heart Disease Related Pulmonary Arterial Hypertension in 45 Children

Variation and significance of serum microRNA-21 level in pediatric pulmonary artery hypertension associated with congenital heart disease

Inhibition of K + Channel Activity in Human Pulmonary Artery Smooth Muscle Cells by Serum from Patients with Pulmonary Hypertension Secondary to Congenital Heart Disease

Inhibition of K|[plus]| Channel Activity in Human Pulmonary Artery Smooth Muscle Cells by Serum from Patients with Pulmonary Hypertension Secondary to Congenital Heart Disease

Changes of Endogenous Nitric Oxide and Hydrogen Sulfide in Plasma of Children with Congenital Heart Disease Complicated with Pulmonary Hypertension